Kevin Quang, DPM
Podiatrist · Tulsa, OKNPI 1376980193
Payments from drug & device makers
What this record shows
7 manufacturers reported payments, led by Pylant Medical at 54.8% of the total. Reporting peaked in 2022 at $1,470 and has fallen 91.7% since, to $122 in 2025.
Across 19 payments — averaging $141.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pylant Medical$1K
- Stryker$950
- Merck$111
- P Bar Medical LLC$102
- Johnson & Johnson$20
- Organogenesis Inc.$17
- plus $14 from 1 others
What the payments were for
- Food & beverage$1,48755%
- Education$1,20045%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pylant Medical | 6 | $1,473 |
| Stryker | 8 | $950 |
| Merck | 1 | $111 |
| P Bar Medical LLC | 1 | $102 |
| Johnson & Johnson | 1 | $20 |
| Organogenesis Inc. | 1 | $17 |
| Boston Scientific | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUGMENT INJECTABLE$495
- Actishield$172
- CITREFIX$137
- ORTHOLOC 2 LAPIFUSE$137
- ANCHORAGE$111
- SIVEXTRO$111
How this compares
$2,687 in reported general payments places this provider in the 60th percentile of 54 podiatrist providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Terbinafine Hcl | 14 | $411 |
| Doxycycline Hyclate | 31 | $409 |
| Clindamycin Hcl | 39 | $388 |
| Methylprednisolone | 37 | $296 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 16 | $257 |
| Meloxicam | 59 | $240 |
| Mupirocin | 21 | $193 |
| Cephalexin | 45 | $190 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 18 | $177 |
| Nortriptyline Hcl | 15 | $91 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Tulsa
- Lisa MogelnickiTulsa$2K
- Robert LeeTulsa$2K
- Mark NahmiasTulsa$1K
- Lauren GiddensTulsa$861
- Allison IskiTulsa$666
- Timothy MaclinTulsa$360
- David CavallaroOklahoma City$22K
- Ahmed BukshEdmond$17K
- Aerial AveryAda$13K
- Patricia BoehleOklahoma City$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.